Short answer
Inhibrx Biosciences, Inc. (INBX) filed an 8-K current report with the SEC on May 11, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Clinical update for INBRX-106 in first-line head and neck squamous cell carcinoma.
Inhibrx Biosciences, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Clinical update for INBRX-106 in first-line head and neck squamous cell carcinoma
- Potential relevance to development strategy and investor expectations for INBRX-106
- Press release dated May 11, 2026 provides the underlying clinical details
Item 8.01 · Other Events
- Interim response rate 44.0% combination vs 21.4% pembrolizumab, a 22.6% absolute improvement
- Three complete responses with INBRX-106 versus none for pembrolizumab alone, supporting potential durability
- Evidence limited to 53 evaluable patients; 15 additional patients await maturity, leaving final efficacy uncertain
- Combination adverse events predominantly low-grade, with no treatment-related deaths reported
- Phase 3 planned for Q3 2026; progression-free survival data expected in Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Inhibrx Biosciences, Inc. 8-K filings
Get the next INBX 8-K as it lands
Follow INBX for push alerts, or ask the research agent what this filing means.